0001513160-12-000094.txt : 20121210 0001513160-12-000094.hdr.sgml : 20121210 20121210122131 ACCESSION NUMBER: 0001513160-12-000094 CONFORMED SUBMISSION TYPE: 10-Q/A PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20120930 FILED AS OF DATE: 20121210 DATE AS OF CHANGE: 20121210 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PHARMOS CORP CENTRAL INDEX KEY: 0000713275 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 363207413 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-11550 FILM NUMBER: 121252368 BUSINESS ADDRESS: STREET 1: 99 WOOD AVENUE SOUTH STREET 2: SUITE 302 CITY: ISELIN STATE: NJ ZIP: 08830 BUSINESS PHONE: 7324529556 MAIL ADDRESS: STREET 1: 99 WOOD AVENUE SOUTH STREET 2: SUITE 302 CITY: ISELIN STATE: NJ ZIP: 08830 FORMER COMPANY: FORMER CONFORMED NAME: PHARMATEC INC DATE OF NAME CHANGE: 19920703 10-Q/A 1 pars10q09302012amend1.htm PHARMOS QUARTERLY REPORT-AMENDED pars10q09302012amend1.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q/A
 
Amendment No. 1
 
x  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2012
or
o  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 0-11550
Pharmos Corporation
(Exact name of registrant as specified in its charter)

 
Nevada
  
36-3207413
  
 
(State or other jurisdiction of incorporation or organization)
  
(IRS Employer Id. No.)
  

99 Wood Avenue South, Suite 302
Iselin, NJ 08830
(Address of principal executive offices)
 
Registrant’s telephone number, including area code: (732) 452-9556

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes x     No o.
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes   x     No    o
 
Indicate by check mark whether registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company as defined in Rule 12b-2 of the Exchange Act.

Large accelerated filer o
 
Non-accelerated filer o
  
Accelerated filer o
 
Smaller reporting company x
  

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes x  No o .

As of November 19, 2012, the Registrant had outstanding 60,170,671 shares of its $.03 par value Common Stock.
 

 
 
 


 
Explanatory Note

This Amendment No. 1 to Form 10-Q for the quarterly period ended September 30, 2012 of Pharmos Corporation is being filed for the sole purpose of checking the box on the cover page to indicate that Pharmos Corporation is a shell company as defined under the Securities Exchange Act and related rules and regulations.

Except as described above, the remainder of the Form 10-Q is unchanged and does not reflect events occurring after the original filing of the Form 10-Q with the Commission on November 19, 2012.
 

 
 
 


 
SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

   
PHARMOS CORPORATION
  
         
         
Date: December 10, 2012
        
   
by:
/s/ Eric W. Fangmann
  
     
Eric W. Fangmann
  
     
Acting Principal Accounting and Financial Officer
  

 
 EX-31.1 2 ex311.htm CERTIFICATION ex311.htm
EXHIBIT 31.1


CERTIFICATE OF ACTING PRINCIPAL EXECUTIVE OFFICER AND
ACTING CHIEF FINANCIAL OFFICER


I, Eric W. Fangmann, certify that:
 
1.  
I have reviewed this quarterly report on Form 10-Q/A of Pharmos Corporation; and
 
2.  
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
 
 

 
/s/          Eric W. Fangmann                                                      
Eric W. Fangmann
Acting Principal Accounting and Financial Officer
(Principal Executive Officer and Principal Financial Officer)
Date:     December 10, 2012